Pap-PRA1 Testing for Progressive Retinal Atrophy in Papillon Dogs

Pap-PRA1 is a specific form of progressive retinal atrophy (PRA) that affects the Papillon dog breed and its Phalène variety, leading to gradual vision loss and, ultimately, irreversible blindness. This inherited disorder can deeply affect a dog's quality of life if not detected early.

Progressive retinal atrophy is a prevalent hereditary eye condition found in many purebred dogs across the United States. However, the exact gene mutation differs by breed. The Pap-PRA1 mutation impacts the photoreceptor cells in the retina, which are essential for sending light and color signals to the brain. Though pups are usually born with normal sight, clinical signs commonly emerge between 4 to 6 years old, typically starting with trouble seeing in dim lighting.

Understanding Pap-PRA1 Progressive Retinal Atrophy

This mutation involves a defect in the CNGB1 gene and follows an autosomal recessive inheritance pattern. Simply put, a dog needs to inherit a mutated gene copy from both parents to develop the condition. Dogs that inherit only one copy act as carriers; they show no signs but can pass the mutation to their puppies.

It’s worth noting that the identified Pap-PRA1 mutation explains about 70% of diagnosed cases, which suggests other yet unknown mutations may also play a role. Genetic testing is an invaluable tool that helps breeders identify affected and carrier dogs, thereby reducing the spread of PRA through responsible breeding strategies.

Which Dogs Are Affected by Pap-PRA1?

The Pap-PRA1 mutation is unique to Papillons and their Phalène variation—distinguished chiefly by their dropped ears, as opposed to the Papillon’s erect ears. The names "Papillon" and "Phalène" derive from French, meaning "butterfly" and "moth," respectively, highlighting their ears' distinctive, wing-like furry appearance.

In the U.S., crossbreeds with Papillon ancestry might carry this mutation silently and can transmit it if bred back to a purebred Papillon. This makes awareness and testing even more crucial, especially for breeders aiming to uphold breed health.

Explaining Inheritance Patterns for Pap-PRA1

Since Pap-PRA1 follows an autosomal recessive pattern, the genetic status of both parents determines the likelihood of affected puppies in a litter. Genetic testing categorizes dogs as clear, carriers, or affected, with breeding pair combinations yielding predictable puppy outcomes:

• Two clear parents: all puppies are clear.
• Two affected parents: all puppies are affected.
• Two carriers: 25% affected, 50% carriers, and 25% clear puppies.
• One clear and one carrier: 50% clear and 50% carriers.
• One clear and one affected: 100% carriers.
• One carrier and one affected: 50% affected and 50% carriers.

How to Screen Your Papillon or Phalène for Pap-PRA1

In the U.S., genetic testing for Pap-PRA1 is readily available through certified laboratories. Many American breeders participate in official DNA testing programs endorsed by breed clubs to reduce PRA prevalence and enhance canine eye health.

The testing procedure involves collecting a DNA sample—usually via a cheek swab or blood draw—carried out by a licensed veterinarian. Samples are sent to approved commercial labs, with results typically returned within 3 to 5 business days. These results classify your dog as clear, carrier, or affected, and reputable breeders share these outcomes to guide safe mating decisions.

Early and regular genetic screening empowers owners and breeders to make informed choices, aiming to gradually eliminate the Pap-PRA1 mutation from the breed’s gene pool while maintaining genetic diversity to support overall health.

For those considering adopting or breeding Papillon puppies in the U.S., it’s essential to ask about Pap-PRA1 testing history and results. Choosing breeders committed to genetic health screening shows dedication to the welfare and longevity of these charming companions.

Find trusted Papillon puppies and Papillon breeders that uphold health testing standards and ethical breeding practices.